Evidence map›Paper›PMID 41821293›Full record

ArticleActa anaesthesiologica Scandinavica2026

Continuous Glucose Monitoring With Real-Time Alerts to Achieve Glycaemic Control in Surgical Patients With Diabetes: Protocol for a Multicentre, Randomised, Clinical Trial.

Casper Pedersen, Annelotte Philipsen, Kirsten Nørgaard, Eske K Aasvang, Christian Sylvest Meyhoff

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Acta anaesthesiologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06314061 (The Effect of Continuous Glucose Monitoring With Real-time Alerts on Glycaemic Control in Surgical Patients With Diabetes), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06314061 phase4completednot on this map

The Effect of Continuous Glucose Monitoring With Real-time Alerts on Glycaemic Control in Surgical Patients With Diabetes: A Randomised, Clinical Multicentre Trial

TypeinterventionalSponsorChristian S. MeyhoffRan2024 to 2026Enrolled200ConditionsDiabetes Mellitus, Dysglycemia, Perioperative ComplicationArmsDexcom G7 Continuous Glucose Monitoring (CGM) System (G7)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Casper PedersenDepartment of Anaesthesia and Intensive Care, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.ORCID 0000-0002-3531-8161
Annelotte PhilipsenSteno Diabetes Center Zealand, Køge, Denmark.
Kirsten NørgaardSteno Diabetes Center Copenhagen, Copenhagen, Denmark.
Eske K AasvangDepartment of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Christian Sylvest MeyhoffDepartment of Anaesthesia and Intensive Care, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.ORCID 0000-0002-4885-4609

Funding

Novo Nordisk Fonden NNF22OC0079038
6 · The paper itself

Abstract

backgroundPerioperative glucose monitoring traditionally relies on intermittent point-of-care (POC) testing, whereas continuous glucose monitoring (CGM) enables real-time glucose assessment with automated alerts for dysglycaemia. CGM remains understudied in hospitalised surgical patients with diabetes. This protocol outlines a clinical trial designed to evaluate the effect of CGM on achieving normoglycaemia in surgical patients with diabetes.

methodsA multicentre, two-group, randomised controlled trial (NCT06314061). Eligible patients are adults with Type 1 or Type 2 diabetes undergoing surgery lasting more than 45 min with an expected hospital stay of at least one night. Patients in the intervention group will be monitored using CGM (Dexcom G7, Dexcom Inc., CA, USA) with active alerts for hyperglycaemia and hypoglycaemia for up to 10 days after surgery during hospitalisation. Patients in the control group will wear a CGM device with glucose values and alerts concealed from the patient and clinical staff. All patients will receive routine diabetes care, including intermittent POC glucose testing, in addition to CGM. The primary outcome is CGM time-in-range between 6.0 and 10.0 mmol/L. Secondary outcomes include the frequency and cumulative duration of hypoglycaemia and hyperglycaemia as well as postoperative complications. A sample size of 200 patients will allow 90% power to detect a 15% relative difference in the primary outcome between groups, with an expected 10% dropout. To ensure standardised use of CGM and to support clinical decision-making during the trial, a trial-specific guideline has been developed, integrating CGM with insulin treatment and POC tests. The guideline recommends intervention for glucose levels < 5.0 mmol/L when trending downward. For CGM glucose levels > 10.0 mmol/L, rapid-acting insulin may be administered according to a sliding scale regimen rather than delaying treatment until the next scheduled POC test.

conclusionThis randomised controlled trial will provide clinical evidence for CGM use by clinical staff to enhance perioperative glycaemic control in surgical patients with diabetes.

trial registrationNCT06314061.

Indexed as

Blood GlucoseContinuous Glucose MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glycemic ControlHumansHyperglycemiaHypoglycemiaMulticenter Studies as TopicRandomized Controlled Trials as TopicBlood Glucose

Identifiers

PMID41821293
PMCPMC12982936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.